China pharma holdings, inc. announced the completion of third party testing of dry eye disease therapeutic device

Haikou, china , nov. 29, 2023 /prnewswire/ -- china pharma holdings, inc. (nyse american: cphi) ("china pharma", or the "company"), an nyse american-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based in china, today announced that its dry eye disease (ded) therapeutic device has passed third-party testing and is preparing to apply for market launch to the national medical products administration (nmpa) of china. according to a disclosure by the shanghai public health clinical center on june 6, 2023, an epidemiological survey of ded showed that approximately 344 million patients are suffering from ded worldwide, accounting for 30% of the total number of ophthalmic outpatient visits, with an annual increase of 10%.
CPHI Ratings Summary
CPHI Quant Ranking